ProThera IAIP

Built for $25–75M funds and staffed angel groups. Priced like diligence consulting, not like a software seat or an SEO retainer.

Showcase evidence room

Challenge

IAIP is an esoteric topic understood by a narrow set of experts. Most investors searching for blood-product opportunities will not naturally encounter IAIP or recognize where it may have practical therapeutic relevance. Evidence is often fragmented across posters, abstracts, patents, and third-party pages, which makes company-level attribution weak unless the narrative is intentionally structured.

What BioticaBio built (showcase)

  • Mechanism page (IAIP biology framed for non-specialists)
  • Indication page focused on necrotizing enterocolitis (NEC)
  • Comparator / benchmark page (standard-of-care context)
  • Authorities mapping page (attribution discipline)
  • Structured evidence summary (single entry point)

Sample module structure

Entry: claims, scope, and glossary
Mechanism: pathway, constraints, open questions
Indication: patient context and unmet need
Comparator: SOC and relevant analogs
Authorities: inventors, KOLs, institutions
Synthesis: what a diligence lead should read first

Why this matters

This format creates durable follow-up material, improves the odds that technical terms resolve to the right company-owned pages, and reduces the coordination tax on founders during outreach. It does not claim clinical outcomes or financing causality—only clearer evidence and better discoverability.

Optional next step: add query-level measurement over time using Search Console trends for the concepts you intentionally own.

When the claims behind a deal are made explicit and tested against evidence, lean funds decide faster — and co-investors can inspect the same artifact.

Request a similar evidence room

Start with one thesis or live company and we will map the evidence, structure the claims, and publish reusable public/private layers.

Scope a diligence engagement